Selective depletion (SD) of alloreactive T cells from allogeneic hematopoeitic stem cell transplants (aHSCT) to prevent graft-versus-host disease (GVHD) without compromising immune reconstitution and anti-tumour responses remains a challenge. Here, we demonstrate a novel SD strategy whereby alloreacting T cells are efficiently deleted ex vivo with adenosine. SD was achieved in HLA mismatched co-cultures by multiple exposures to 2mM adenosine over seven days. Adenosine depleted greater than to 90% of alloproliferating T cells in mismatched, haploidentical, and matched sibling pairs while conserving response to 3 rd party antigens.
Abstract:
Selective depletion (SD) of alloreactive T cells from allogeneic hematopoeitic stem cell transplants (aHSCT) to prevent graft-versus-host disease (GVHD) without compromising immune reconstitution and anti-tumour responses remains a challenge. Here, we demonstrate a novel SD strategy whereby alloreacting T cells are efficiently deleted ex vivo with adenosine. SD was achieved in HLA mismatched co-cultures by multiple exposures to 2mM adenosine over seven days. Adenosine depleted greater than to 90% of alloproliferating T cells in mismatched, haploidentical, and matched sibling pairs while conserving response to 3 rd party antigens.
Alloreactive CD4 and CD8 T cells were targeted for depletion while NK and B cells were preserved. Our novel approach also preserved non-alloreactive naïve, central and effector memory T cell subsets, Tregs, and notably preserved T cell responses against DNA viruses that contribute to transplant related mortality after aHSCT. Additionally, T cells recognizing leukemia-associated antigens were efficiently generated in vitro from the cell product post SD.
This study is the first to demonstrate that adenosine depletion of alloactivated T cells maintains a complete immune cell profile and recall viral responses. Expansion of tumor antigen specific subsets post-depletion opens the possibility of generating T cell products capable of graft-versustumor responses without causing GVHD.
Introduction
The focus of any strategy to optimize the outcome of allogeneic stem cell transplant (SCT) is to manipulate the incoming donor T cell repertoire so as to prevent graft versus host disease (GVHD) provoked by major and minor recipient histocompatibility antigens (HLA)
while preserving cells capable of restoring cellular immunity, especially against microbial infections, common viruses, and tumors in the case of transplants for malignant disease. Current haploidentical transplant approaches to prevent GVHD, which preserve at least some protective immunity against viral reactivation and disease recurrence, range from T cell depletion, 1 intensive post-transplant immunosuppression, 2 or in vivo elimination of alloreacting T cells early post graft using high dose cyclophosphamide. 3, 4 An important contribution to the successful suppression of GVHD is the preservation of regulatory T cells (Tregs), which have a selective advantage in suppressing GVHD while permitting immune recovery. [5] [6] [7] An alternative approach is the ex vivo selective depletion (SD) of T cells responsible for the donor's alloresponse against recipient mononuclear cells. 8 In this approach the donor lymphocytes are cocultured with either irradiated lymphocytes from the recipient in a mixed lymphocyte reaction (MLR) or other irradiated recipient mononuclear cells in a modified MLR (mMLR). Alloactivated donor T cells can then be eliminated or rendered non-functional by antibodies or immunotoxins targeting activation antigens (CD25, CD69), or by photodepletion of activated T cells. 9 Off-target depletion of the crucial CD25 + Treg population along with poor depletion efficacy, possibly due to down-regulation of targeted antigens, has hampered the success of immune-magnetic and immunotoxin approaches. Photodepletion with a TH9402-based dye failed to improve outcomes in HLA matched sibling transplants but has shown promise in haploidentical transplants. [10] [11] [12] An effective, immune modulating strategy for SD which conserves Tregs and can be consistently and easily reproduced in clinical scale has not yet been achieved.
Here, we present a novel strategy for allodepletion employing ex vivo treatment of alloreacting donor T cells with adenosine. Adenosine is a purine nucleoside FDA-approved for treatment of supraventricular tachycardia. In physiological conditions adenosine plays an integral role in thymic function and peripheral tissue homeostasis. In hypoxic and inflammatory environments, such as the tumor microenvironment, adenosine regulates inflammation, inducing tolerance and immune suppression. [13] [14] [15] Here we exploited the immune regulatory effects of adenosine for prevention of GVHD and demonstrate that pharmacological doses of adenosine efficiently deplete activated alloreactive T cells from mismatched or haplo identical donor lymphocyte populations while retaining desirable cell subsets essential for normal immune reconstitution.
Results

Adenosine selectively depletes allo-activated T cells
Healthy donor lymphocytes were stimulated with randomly mismatched DC in mMLR assay. T cells were analyzed for CD25 expression to measure activation and CFSE dilution to measure proliferation. Adenosine, a short-lived biological agent, was added at 48 hour intervals (days 1, 3, and 5) in concentrations varying from 10uM to 1mM. Suppression of CD25
expression was observed at the highest 1mM concentration of adenosine (Fig. 1a) . In subsequent experiments 2mM adenosine was used to ensure suppression of activation and proliferation.
Multiple treatments of adenosine over a five day period were necessary to achieve sustained suppression of T cell proliferation (Fig. 1b) . A single early treatment on the second day of culture suppressed activation, but T cell proliferation was noticed on days 8-10 indicating the presence of a residual group of late-responding cells. A single late treatment (day 5) only eliminated about half of proliferating cells. Combining the early and late treatments by administering adenosine on days 1, 2, and 5 after establishing mMLR successfully suppressed proliferation up to 5 days after the final treatment.
To explore cytotoxic effects of adenosine on activated T cells, lymphocytes were stimulated with anti-CD3/CD28 beads and treated with adenosine ( Fig. 1c) . Vivid viability staining revealed major reduction in viable lymphocytes and increased cell debris in adenosine treated samples. Direct induction of apoptosis was assessed by culturing lymphocytes from four healthy donors either alone, with a mix of DC from three mismatched donors, or anti-CD3/CD28
beads. After 72 hours, half of the cultures were incubated with 2mM adenosine for 5 minutes before staining with Annexin V and PI. Paired T test statistical analysis showed a significant increase in PI+AnnexinV+ cells in both allo-stimulated and bead-stimulated cultures (P=0.04,
P=0
.02) but no significant change in this population for unstimulated lymphocytes (P=0.6, Table   S1 ). These results suggest that adenosine is toxic towards and capable of depleting T cells activated by allo-or anti-CD3/CD28 stimulation. The lack of significant induction of apoptosis in unstimulated T cells suggests that this depletion is selective to activated cells, but does not definitively discount that some non-activated, non-proliferating population of cells may also be affected.
From these experiments, a standard SD protocol was devised in which cultures established on day 0 were treated with 2mM adenosine as a 2X solution on days 1, 2, and 5. In Impact of adenosine on viability and individual lymphocyte subsets Allodepleted cultures generated from three donors were tested for recognition of peptide libraries for CMV antigens pp65 and IE-1, EBV antigens BZLF1 and EBNA1, and adenovirus antigen AD5 (Fig. 5a ). Viral peptide recognition measured by IFN-γ production varied between donors. Antigen specific T cell responses to all viruses were retained and in 11/15 instances antigen-specific T cell frequencies were increased after adenosine-mediated allodepletion.
Transfer of ex vivo expanded viral-specific T cells is a promising strategy to improve immune reconstitution after stem cell transplant made increasingly accessible by recent innovations in cell culture expansion. 17 Since viral-specific T cells were preserved after adenosine treatment, our approach serves as a useful platform for expanding viral-specific T cells free of the risk of GVHD for adoptive transfer. To test this, cultures depleted with adenosine were washed and stimulated twice at weekly intervals with autologous DC pulsed with pp65 and IE-1 peptides. One week after the second stimulation, products were rested overnight and tested for reactivity against pp65, IE-1, or control WT1 as determined by the expression of TNF-α and IFN- 6 hour post peptide stimulation by flow cytometry. Enrichment of CMV-reacting cells, particularly polyfunctional T cells producing both TNF-α and IFN-, was achieved in three donors (Fig. 5b) .
T cells targeting leukemia-associated antigens (LAA), WT1 and PRAME can be generated from allodepleted products
Graft lymphocyte-mediated anti-tumor immune responses are an essential function of the allograft in preventing relapse. 18 T cells in particular can exhibit powerful toxicity against malignant cells if targeted to recognize tumor-identifying antigens. Tumor antigens such as PRAME and WT1 are highly expressed in some leukemias, but precursor memory T cells recognizing these antigens are infrequent to nonexistent in healthy donors.
To generate LAA-specific cells, lymphocytes allodepleted against mismatched DCs with adenosine were stimulated twice at weekly intervals with autologous DCs transduced to express PRAME or WT1 peptide. Polyfunctional recognition of PRAME and WT1 antigens was achieved in CD4 + and CD8 + T cell subsets of 3 donors (Figs. 6a,b) , establishing the feasibility of In three experiments, SD with adenosine reduced alloreactivity below that of untreated controls in both haploidentical and matched sibling mMLR (Fig. 7) . Statistical analysis revealed that in the haploidentical setting, proliferation of the 'donor' allodepleted product against 'recipient' APCs was significantly decreased compared to undepleted controls (*, P=0.011) while proliferation against 3 rd party APCs was not significantly affected (ns, P=0.073). In the matched sibling setting, statistics revealed no significant differences between allodepleted cultures and controls, which is likely due to the low initial alloreactivity of Donor 2 against the matched sibling recipient. Further studies and in vivo models may provide a clearer case for employing this strategy in matched sibling transplants.
Discussion
In this study we show that pharmacological concentrations of adenosine can selectively and homeostasis. 20 It is worth noting that several artificial adenosine receptor ligands which might further boost adenosine-mediated SD have been synthesized and are available commercially. 23 We hypothesized that the immunosuppressive properties of adenosine might be harnessed to selectively deplete alloreacting cells from SCT in order to create GVHD-free cell products, particularly in haplo SCT where robust methods to prevent GVHD are needed. Here we demonstrated that adenosine blocked both the initiation of the alloresponse and also prevented subsequent proliferation of alloreactive T cells (Figs. 1a,b ) in dose and time dependent manner.
Effective depletion of alloreactive cells was achieved by treating the cultures with 2mM adenosine on days 1, 2 and 5 of coculture. This method also depleted lymphocytes stimulated with anti-CD3/CD28 beads, demonstrating that adenosine is toxic to activated T cells at millimolar concentrations (Fig. 1c) . The abrogation of alloresponse was maintained upon rechallenge of depleted cultures against the original stimulator DCs (Fig. 2) . Phenotypic analysis revealed that while removing alloreactive T cells, adenosine preserved B and NK cells as well as naïve and memory T cell repertoires (Fig. 3) . Memory T cells provide important immune competence against a variety of infectious agents including DNA viruses such as CMV, which complicate post-transplant outcome. Effective SD must retain these cells to prevent reactivation and opportunistic infection. We therefore tested the SD product for CMV, EBV, and AD5 reactivity. In three independent experiments we observed that allodepleted cultures maintained or sometimes enriched these viral-specific T cells. Using CMV as a model, we also showed that these peptide-recognizing cells can be expanded ex vivo through antigen-specific stimulation and exhibit the properties of adoptively transferred T cells used to control CMV after stem cell transplantation (Fig. 4) . 24 It has been shown that donor T cells recognizing leukemia antigens are implicated in the GVL response, which is in part responsible for relapse-free survival after SCT. 18 Particular antigens of interest are WT1 and PRAME, both of which are overexpressed in acute leukemias. 25 We therefore explored the ability of SD cultures to generate T cell responses to these antigens.
Using autologous DCs transduced with lentiviral vectors to express and present naturally processed epitopes of the target antigens, we showed in 3 experiments that CD4 + and CD8 + T cells specifically recognizing WT1 and PRAME can be elicited from SD cell products (Fig. 6 ).
This result suggests that cultures depleted of alloreactive cells with adenosine could safely be used for adoptive transfer contributing to immune surveillance and protection against relapse while avoiding GVHD.
Our findings indicate that adenosine SD preserves important immune responses which can determine SCT outcome. Furthermore technologies are being developed to generate antigen specific T cells to treat or prevent viral reactivation 24, 26 and leukemia relapse after SCT. 27, 28 Such cell products may still retain harmful alloreactivity, particularly in the haplo setting. Our data suggests that preemptive use of adenosine to deplete alloreactive cells could improve the quality and purity of such products.
In this study we employed mature DC as stimulator APCs for their high expression of MHC and co-stimulatory molecules. DC proved highly effective stimulators, to the point of inducing background proliferation in autologous controls (Figs. 2,7) . In designing selectively depleted SCT for hematopoietic malignancy, the choice of stimulator cell would determine the degree of antigenic overlap between the stimulator and the malignancy. In both HLA matched and mismatched settings, T cell recognition of minor histocompatibility antigens contributes to both GVHD and GVL. 29 Thus, employing an APC sharing lineage with a patient's specific tumor may unfavorably deplete donor T cells recognizing minor antigens identifying the tumor, reducing the GVL response. Selective depletion has been achieved with a variety of stimulator types such as unmanipulated PBMCs, 30 ex vivo expanded CD8 + T lymphocytes, 31 and EBVtransformed B lymphoblastoid cell lines (EBV-LCL). 32 Further work is required to identify the best APC for specific situations.
The concept of using SD to reduce GVHD and maintain GVL is not new. Clinical studies employing anti-CD25 conjugated immunotoxin to eliminate CD25-expressing alloactivated T cells in ex vivo mMLR have been conducted previously in both haploidentical and matched sibling transplants. 32, 33 The studies in haploidentical transplants found that infusion of SD donor lymphocytes significantly aided immune reconstitution, 32 but persisting GVHD was observed in matched sibling transplants. 33 Further studies revealed that donor CD4 + CD25 + FOXP3 + Tregs significantly contributed to protection against acute GVHD in these transplants. 6 Our experiments show that SD with adenosine spares these critical Tregs, highlighting the potential for GVHD protection by this approach. Subsequent clinical studies adopted a photo depletion technique which targeted alloactivated cells in mMLR by their reduced ability to efflux a photosensitizing TH9402-based dye. 31, 34 While photo depletion exhibited positive results in haploidentical transplant, 34, 35 off-target depletion of CD4 + CM T cells in matched sibling transplants was associated with increased rate of infection and transplant related mortality. 10 We have shown that adenosine specifically targets alloactivated T cells in mMLR and does not significantly deplete resting memory T cells. Importantly, using adenosine we achieved SD in both haploidentical and matched sibling mMLR (Fig. 7) . In the matched sibling setting, we observed significant reduction in allo-responses between some two out of three donor/recipient pairs, while the initial alloreactivity was very low in one case. Further studies and in vivo models may provide a clearer case for employing this strategy in matched sibling transplants.
In conclusion, adenosine-based SD represents a readily applicable, inexpensive and robust approach to the persisting problem of refining the T cell content of the allograft to optimize SCT outcome for both HLA matched and mismatched donor-recipient pairs. The protocol is scalable and all reagents are GMP compliable. 
Ex vivo expansion of CMV-specific T cells
To expand effector T cells with specificity against CMV antigens, lymphocytes allodepleted with adenosine were primed twice at weekly interval with mature autologous DC pulsed with CMV pp65 and IE-1 pepmix (JPT) at a responder to stimulator ratio of 5:1. Cultures received IL-7 (10 ng/mL) and IL-15 (10 ng/mL) during first priming and IL-2 (10 IU) in addition to IL-7 and IL-15 during second priming step. Resulting effector T cell cultures were tested for reactivity against CMV pp65 and IE-1 antigens as described above.
Ex vivo generation of leukemia associated antigen-specific T cells
To generate and expand leukemia associated antigen PRAME and WT1 specific effector T cells we used autologous DC as APC engineered with lentivirus to express these antigens as described in the supplementary methods. Cells were harvested from adenosine treated mMLR cultures on day 7 and primed twice at weekly interval with indicated target antigen-transduced mature autologous DC at a responder to stimulator ratio of 5:1. Cultures were expanded in the presence of cytokines as described for CMV-specific T cells. Resulting effector T cell cultures were tested for reactivity against autologous DC pulsed with peptide libraries derived from corresponding target antigen or irrelevant control antigen.
Statistical analysis
Graphs were plotted using Graphpad Software (La Jolla, CA). Data are presented as mean, with standard error bars where appropriate. Statistical analysis was performed either using paired or unpaired Student t test where P ≤ 0.05 was considered statistically significant (*, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001). : Leukemia associated antigen specific T cells were generated from allodepleted cultures. Adenosine depleted lymphocytes from 6 mismatched donor-recipient pairs were stimulated twice at weekly interval with autologous DCs transduced with a lentiviral vector expressing PRAME or WT1 to generate and enrich antigen-recognizing T cells. Antigen specificity was tested against DCs transduced with the cognate antigen PRAME or WT1, or irrelevant control antigen in a 6 hour coculture assay followed by intracellular flow cytometry for cytokine production analysis. Production of IFN- and TNF-α in recognition of cognate antigen over background control in CD4 + and CD8 + T cell subsets is presented for (a) PRAME-specific cultures and (b) WT1-specific cultures from 3 donor-recipient pairs. 
